FDA grants IDE approval for Renerva’s trial of nerve capping device
December 4, 2025
The trial will enroll patients who are undergoing nerve management procedures for severe neuropathic pain.
The trial will enroll patients who are undergoing nerve management procedures for severe neuropathic pain.
Avance is an acellular nerve scaffold for the treatment of adult and pediatric patients aged 1 month or older with sensory, mixed, and motor peripheral nerve discontinuities
Today, NeuroVice announced that PATI is now commercially available, marking a breakthrough moment for millions of patients living with focal and grand-mal seizures.
SURREY, BC, Dec. 4, 2025 /PRNewswire/ – mlHealth 360 today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance (K250694) for Scaida BrainCT-ICH, an AI-powered triage solution designed to address critical bottlenecks in acute care radiology.
Preliminary studies find derivatives of the compound, known as verticillin A, can kill some types of glioma cells.
The test, which runs on the cobas liat system, is said to deliver results in 15 minutes.
The Vanquish device’s clinical data demonstrated an elimination of MRI visible intermediate risk disease in 91% of patients after a single procedure.
Two related studies published today in Nature Metabolism show that a specialized intracellular recycling mechanism—chaperone-mediated autophagy (CMA)—is essential for muscle health.
High levels of calcium are toxic to cells and contribute to loss of neurons in Alzheimer’s disease. A new study published in JCI Insight identifies a mechanism through which the young brain protects itself against high calcium levels, and it could help scientists learn how to protect the brain from this devastating neurodegenerative condition.
It’s not often that a pathologist gets to make a diagnosis that works for the patient by preventing treatment from occurring.